Breaking News

Piramal Pharma Solutions Completes 1,500th ADC Batch at Grangemouth Facility

Site has produced hundreds of distinct bioconjugates and supports clinical, commercial, and non‑GMP manufacturing activities.

Author Image

By: Charlie Sternberg

Associate Editor

The Grangemouth site team celebrates the completion of the 1,500th ADC batch.

Piramal Pharma Solutions, a global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd., recently completed its 1,500th antibody-drug conjugate (ADC) batch at its dedicated bioconjugate development and manufacturing facility in Grangemouth, UK.

The site has produced hundreds of distinct bioconjugates and supports clinical, commercial, and non‑GMP manufacturing activities. Technical guidance for these programs is provided by subject matter experts from the Science Collective.

The Grangemouth facility holds accreditations from regulatory agencies including the US FDA and the MHRA, reflecting its established compliance record. Its capabilities enable the production of bioconjugate therapies intended for both clinical development and commercial supply.

More Piramal News

Earlier this year, Piramal Pharma Solutions introduced a tablet-in-capsule drug delivery system at its drug product facilities in Pithampur and Ahmedabad, India.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters